↓ Skip to main content

Dove Medical Press

Article Metrics

Long-term safety of bilateral targeted lung denervation in patients with COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, July 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
16 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
23 Mendeley
Title
Long-term safety of bilateral targeted lung denervation in patients with COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, July 2018
DOI 10.2147/copd.s158748
Pubmed ID
Authors

Arschang Valipour, Sherwin Asadi, Christophe Pison, Marie Jondot, Romain Kessler, Khaled Bennedif, Gaetan Deslee, Margaux Verdier, Dirk-Jan Slebos, Martin Mayse

Abstract

Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD which ablates parasympathetic pulmonary nerves running along the outside of the two main bronchi with the intent of inducing permanent bronchodilation. The goal of this study was to evaluate the feasibility and long-term safety of bilateral TLD during a single procedure. This prospective, multicenter study evaluated 15 patients with moderate-to-severe COPD (forced expiratory volume in 1 s [FEV1] 30%-60%) who underwent bilateral TLD treatment following baseline assessment without bronchodilators. The primary safety end point was freedom from documented and sustained worsening of COPD directly attributable to TLD up to 1 year. Secondary end points included technical feasibility, change in pulmonary function tests, exercise capacity, and health-related quality of life. Follow-up continued up to 3 years for subjects who reconsented for longer-term follow-up. A total of 15 patients (47% male, age 63.2±4.0 years) underwent TLD with a total procedure time of 89±16 min, and the total fluoroscopy time was 2.5±2.7 min. Primary safety end point of freedom from worsening of COPD was 100%. There were no procedural complications reported. Results of lung function analysis and exercise capacity demonstrated similar beneficial effects of TLD without bronchodilators, when compared with long-acting anticholinergic therapy at 30 days, 180 days, 365 days, 2 years, and 3 years post-TLD. Five of the 12 serious adverse events that were reported through 3 years of follow-up were respiratory related with no events being related to TLD therapy. TLD delivered to both lungs in a single procedure is feasible and safe with few respiratory-related adverse events through 3 years.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 13%
Other 3 13%
Student > Ph. D. Student 3 13%
Professor 3 13%
Student > Bachelor 1 4%
Other 3 13%
Unknown 7 30%
Readers by discipline Count As %
Medicine and Dentistry 14 61%
Nursing and Health Professions 1 4%
Unspecified 1 4%
Engineering 1 4%
Unknown 6 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2018.
All research outputs
#889,750
of 14,683,530 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#57
of 1,789 outputs
Outputs of similar age
#29,064
of 272,518 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#5
of 57 outputs
Altmetric has tracked 14,683,530 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,789 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,518 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.